Article
Chemistry, Multidisciplinary
S. Park, J. Y. Park, J. H. Nahm, G. Kim, Y. L. Cho, W. J. Kang, J. Key
Summary: This study prepared nintedanib-loaded poly (lactic-co-glycolic acid)-based discoidal polymeric particles (Nib-PLGA-DPPs) for the treatment of idiopathic pulmonary fibrosis (IPF). The Nib-PLGA-DPPs showed improved therapeutic efficacy in reducing fibrosis and inflammation compared to nintedanib alone.
MATERIALS TODAY CHEMISTRY
(2022)
Article
Immunology
Emily Fraser, Laura Denney, Agne Antanaviciute, Karl Blirando, Chaitanya Vuppusetty, Yuejuan Zheng, Emmanouela Repapi, Valentina Iotchkova, Stephen Taylor, Neil Ashley, Victoria St Noble, Rachel Benamore, Rachel Hoyles, Colin Clelland, Joseph M. D. Rastrick, Clare S. Hardman, Nasullah K. Alham, Rachel E. Rigby, Alison Simmons, Jan Rehwinkel, Ling-Pei Ho
Summary: Monocytes in idiopathic pulmonary fibrosis (IPF) patients exhibit a distinct immunophenotype from age-matched controls, with an activated type I interferon pathway that may contribute to driving chronic inflammation and fibrosis. These findings strengthen the potential role of monocytes in the pathogenesis of IPF.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Paolo Cameli, Valerio Alonzi, Miriana d'Alessandro, Laura Bergantini, Elena Pordon, Marco Guerrieri, Rosa Metella Refini, Piersante Sestini, Elena Bargagli
Summary: This study aimed to investigate the effectiveness and safety of nintedanib in reducing functional disease progression in patients with IPF and PF-ILD. The results showed that nintedanib significantly reduced the decline rate of FVC in IPF and PF-ILD patients, but had no significant impact on FPF patients. Survival analysis revealed that gender and impaired lung function influenced the survival of patients.
Article
Respiratory System
Manon Belhassen, Faustine Dalon, Maeva Nolin, Eric Van Ganse
Summary: This study using data from the French National Health System evaluated outcomes in IPF patients newly treated with pirfenidone or nintedanib in 2015-2016. Results showed that compared to pirfenidone, nintedanib treatment was associated with a higher risk of all-cause mortality, acute respiratory-related hospitalisations, and a lower risk of treatment discontinuation at 12 months.
RESPIRATORY RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Prachi Umbarkar, Anand P. Singh, Sultan Tousif, Qinkun Zhang, Palaniappan Sethu, Hind Lal
Summary: Nintedanib (NTB) is an FDA-approved tyrosine kinase inhibitor for pulmonary fibrosis, and study shows its potential in reducing cardiac fibrosis and improving cardiac function in a murine heart failure model, suggesting its promising application in treating HF patients.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Cell Biology
Kazutaka Takehara, Yasuhiko Koga, Yoshimasa Hachisu, Mitsuyoshi Utsugi, Yuri Sawada, Yasuyuki Saito, Seishi Yoshimi, Masakiyo Yatomi, Yuki Shin, Ikuo Wakamatsu, Kazue Umetsu, Shunichi Kouno, Junichi Nakagawa, Noriaki Sunaga, Toshitaka Maeno, Takeshi Hisada
Summary: In patients with IPF, the discontinuation rate of nintedanib treatment due to adverse events is higher than that of pirfenidone treatment. Better management of adverse events with nintedanib leads to more continuous treatment, preventing disease progression and acute exacerbations, thus improving prognosis for IPF patients.
Article
Medicine, General & Internal
Donato Lacedonia, Michele Correale, Lucia Tricarico, Giulia Scioscia, Silvia Romana Stornelli, Filomena Simone, Massimo Casparrini, Natale Daniele Brunetti, Maria Pia Foschino Barbaro
Summary: IPF is a chronic progressive disease that leads to respiratory failure and death within years, particularly poor in patients with PH. Severity of PH is associated with reduction of DLCO value and increase of the GAP index. Echocardiographic stratification may be useful in predicting prognosis and determining specific treatments.
INTERNAL AND EMERGENCY MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Haitao Huang, Jingyu Jiang, Ruihan Chen, Yimou Lin, Hui Chen, Qi Ling
Summary: Hepatic macrophage TAM receptor signaling plays a critical role in liver diseases, with both anti-inflammatory and tissue repair effects, as well as potential promotion of chronic inflammation, fibrosis, and tumorigenesis.
LIVER INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Carolin K. Watson, Daniela Schloesser, Katrin Fundel-Clemens, Carmen Lerner, Svenja Gabler, Praveen Baskaran, Christian T. Wohnhaas, Stefanie Dichtl, Heinrich J. Huber, Kjetil Ask, Florian Gantner, Coralie Viollet, Matthew J. Thomas, Fidel Ramirez, Peter J. Murray, Karim C. El Kasmi
Summary: This study aims to identify the phenotypes of profibrotic and prohomeostatic macrophages and discover new therapeutic approaches for fibrotic disease. By combining in vivo and in vitro RNA-sequencing methods, the study found that nintedanib can promote the expression of IL-4/IL-13 pathway genes in lung macrophages, leading to tissue repair.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
(2023)
Article
Respiratory System
Timothy M. Dempsey, Stephanie Payne, Lindsey Sangaralingham, Xiaoxi Yao, Nilay D. Shah, Andrew H. Limper
Summary: Since their approval in 2014, the adoption of pirfenidone and nintedanib in the United States has been low, which may be associated with the high out-of-pocket costs.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2021)
Article
Immunology
Yupeng Li, Yaowu He, Shibin Chen, Qi Wang, Yi Yang, Danting Shen, Jing Ma, Zhe Wen, Shangwei Ning, Hong Chen
Summary: This study found that S100A12 might be an efficient disease severity and prognostic biomarker in patients with IPF. It is highly expressed in monocytes, but downregulated in lung tissue. Ten genes interacting with S100A12 and the co-expressed genes S100A8 and S100A9 are significantly associated with lung function, survival rates, and survival time in IPF patients. The prognostic predictive value of S100A12 is superior to S100A8 and S100A9 in IPF patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Respiratory System
Pavo Marijic, Larissa Schwarzkopf, Lars Schwettmann, Thomas Ruhnke, Franziska Trudzinski, Michael Kreuter
Summary: This study compared patients treated with pirfenidone and nintedanib in terms of mortality, hospitalization, and healthcare costs, finding no significant differences between the two drugs in these patient-related outcomes.
RESPIRATORY RESEARCH
(2021)
Article
Chemistry, Medicinal
Motoyasu Kato, Shinichi Sasaki, Misa Tateyama, Yuta Arai, Hiroaki Motomura, Issei Sumiyoshi, Yusuke Ochi, Junko Watanabe, Hiroaki Ihara, Shinsaku Togo, Kazuhisa Takahashi
Summary: The study showed that poor performance status can lead to discontinuation of nintedanib treatment after 12 months, but long-term nintedanib treatment may be beneficial for patient survival.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Critical Care Medicine
Yosafe Wakwaya, Deepa Ramdurai, Jeffrey J. Swigris
Summary: Chronic cough in patients with IPF may involve multiple mechanisms, including comorbid conditions and IPF itself. Diagnostic and management approaches need to be multi-faceted, but may lack robust data support.
Article
Genetics & Heredity
Kota Araki, Rie Kinoshita, Nahoko Tomonobu, Yuma Gohara, Shuta Tomida, Yuta Takahashi, Satoru Senoo, Akihiko Taniguchi, Junko Itano, Ken-ichi Yamamoto, Hitoshi Murata, Ken Suzawa, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Kouichi Ichimura, Masahiro Nishibori, Nobuaki Miyahara, Shinichi Toyooka, Masakiyo Sakaguchi
Summary: S100A8/A9 plays an active role in the development of pulmonary fibrosis by promoting fibroblast proliferation, differentiation into myofibroblasts, and collagen production, through its receptor RAGE. Targeting S100A8/A9 may be a promising therapy for interstitial pneumonia with fibrosis.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2021)
Article
Immunology
Jun Cui, Cheng Chen, Xiao Zhou, Wenju Shan, Yuhong Jian, Panpan Li, Yang Sun, Wei Yi
Summary: Bone marrow mesenchymal stem cells (BMSCs) are a promising therapy for sepsis, but metabolic syndromes threaten their effectiveness. This study investigated the potential of small extracellular vesicles from high-fat diet BMSCs in sepsis-induced liver-heart axis injury.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Binbin Zhu, Angyang Cao, Chunqu Chen, Weijian Zhou, Wenjun Luo, Yu Gui, Qinwen Wang, Zhipeng Xu, Jianhua Wang
Summary: GM6001 alleviates postoperative cognitive deficits and neuroinflammation, preserves blood-brain barrier integrity, and rescues aquaporin-4 mislocalization. MMP-9 inhibition plays a dual role in cognitive protection through direct anti-neuroinflammatory effects and regulation of aquaporin-4 membrane distribution.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Anika Sood, Valencia Fernandes, Kumari Preeti, Shruti Rajan, Dharmendra Kumar Khatri, Shashi Bala Singh
Summary: S1PR2 inhibitor improves cognitive function and skews microglia toward anti-inflammatory phenotype in type 2 diabetic mice, promising to be a potential therapy for neuroinflammation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Haochun Guo, Ran Yu, Haijun Zhang, Wanpeng Wang
Summary: Radiation therapy is an effective treatment for thoracic malignancies, but it can cause radiation-induced lung injury (RILI), including radiation pneumonitis (RP) and radiation pulmonary fibrosis (RPF). The damage to normal lung cells during radiation treatment leads to a pulmonary inflammatory response, resulting in RP and RPF.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Guanghui Wang, Haotian Zheng, Yunzhi Xiang, Yadong Wang, Kai Wang, Xiaoyang Ren, Jiajun Du
Summary: This study identified a T-cell synthetic driver-associated prognostic model that accurately predicted prognosis and effectiveness of immunotherapy in LUAD patients. It also highlighted the role of LDHA in promoting tumor cell proliferation, invasion, and resistance to treatment, as well as its involvement in immune escape within the tumor microenvironment. These findings provide a promising new therapeutic strategy for LUAD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Bowen Wei, Aihua Wang, Wei Liu, Qingyun Yue, Yihua Fan, Bin Xue, Siwei Wang
Summary: This study systematically analyzed the association between pSS and cuproptosis, established a predictive model based on 5 genes, explored the pathogenic mechanisms and novel therapeutic strategies for pSS, and identified EED, CBL, and NFU1 as potential targets for treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Nusrit Iqbal Andrabi, Aminur R. Sarkar, Syed Assim Haq, Diljeet Kumar, Dilpreet Kour, Diksha Saroch, Sanket Kumar Shukla, Ajay Kumar, Asha Bhagat, Asif Ali, Gurleen Kour, Zabeer Ahmed
Summary: Koenimbine and its novel semi-synthetic derivative 1G demonstrate significant anti-inflammatory effects by downregulating the nuclear factor kappa-B (NF-kappa B) signaling pathway.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Jing-Mei Lu, Xiang Xu, Fumie Aosai, Ming-Yue Zhang, Lian-Xun Piao
Summary: This study found that arctiin can improve allergic acute liver injury caused by T.g.HSP70 by inhibiting TLR4 signaling and reducing the production of inflammatory mediators.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Minxuan Xu, Fang Shi, Yongshen Gao, Shumei Han, Chensuo Huang, Qinsheng Hou, Xiaoweng Wen, Bengshi Wang, Zhenyu Zhu, Lei Zou, Mingxin Xiong, Wei Dong, Jun Tan
Summary: There is a growing body of research highlighting the involvement of metabolic imbalance and the inflammatory response in the advancement of colitis. This study recognizes arabinose as a significant protector of the intestinal mucosal barrier, reducing damage to the intestines. In addition, lower levels of arabinose in the bloodstream are associated with a higher severity of inflammatory bowel disease and colorectal cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yueqing Han, Haoxin Song, Yanshan Li, Rongxin Li, Ling Chen, Bo Gao, Yijun Chen, Shuzhen Wang
Summary: The combination of tetracycline antibiotics, demeclocycline (D), chlortetracycline (C), and minocycline (M), showed therapeutic potential against liver fibrosis by inhibiting the activation of hepatic stellate cells and the MAPK signaling. This study suggests that tetracyclines may be repurposed for the treatment of liver fibrosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yu Li, Hailing Liu, Danwen Zhao, Danjie Zhang
Summary: Chronic stress can lead to lung injury, with the spleen playing a crucial role. This study found that the spleen contributes to chronic restraint stress-induced lung injury, and splenic CD11b+ cells may be an important factor in this process.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yingqian Mi, Mengyan Tang, Qiong Wu, Yinan Wang, Qihui Liu, Pei Zhu, Xiaoyang Xue, Yuntong Liu, Xinyu Chai, Yuyang Hou, Dongmei Yan
Summary: BCG therapy can induce macrophage polarization to the M1 type, and NMAAP1 plays a crucial role in this process by regulating glycolysis and HIF-1α expression. This promotes the antitumor effect of macrophages.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Xiaosheng Liu, Tingxia Lv, Xiuxia Li, Jing Xue, Ling Lin, Lianfeng Lu, Xiaodi Li, Yang Yang, Yuanni Wu, Qiang Wei, Wei Cao, Taisheng Li
Summary: LLDT-8 exhibits notable efficacy in alleviating immune activation in both an in vivo animal model and in vitro human cell experiments, suggesting its potential as a drug for managing systemic immune activation associated with SIV/HIV infection.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Honghong Yu, Qi Li, Huimin Zhu, Chang Liu, Weiwei Chen, Lingyun Sun
Summary: The activation of the inflammasome plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE), and mesenchymal stem cells (MSC) have been shown to alleviate SLE by suppressing inflammasome activation. This study found that the NLRP3 inflammasome was activated in macrophages from SLE patients and mice, and its activation correlated with disease activity. After MSC transplantation, the severity of SLE was reduced, and NLRP3 inflammasome activation was inhibited. These findings suggest that MSC suppress inflammasome activation and provide a potential therapeutic target for SLE.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Wei Zhou, Dan Zeng, Shunan Liu, Yunxia Huang, Fenglin Lv, Weikang Zhou
Summary: This study found that inhibiting HDAC3 can protect the skin from atopic dermatitis by activating the Nrf2 transcription to upregulate Nrf2/HO-1 signaling pathway activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)